Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

bioAffinity Technologies (BIAF) Leases (2023 - 2026)

bioAffinity Technologies has reported Leases over the past 4 years, most recently at $1.2 million for Q1 2026.

  • Quarterly Leases fell 8.47% to $1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Mar 2026, down 8.47% year-over-year, with the annual reading at $1.2 million for FY2025, 8.47% down from the prior year.
  • Leases was $1.2 million for Q1 2026 at bioAffinity Technologies, roughly flat from $1.2 million in the prior quarter.
  • Over five years, Leases peaked at $1.3 million in Q4 2023 and troughed at $565030.0 in Q2 2025.
  • The 4-year median for Leases is $1.3 million (2023), against an average of $1.1 million.
  • Year-over-year, Leases grew 2.54% in 2024 and then crashed 56.34% in 2025.
  • A 4-year view of Leases shows it stood at $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then decreased by 8.47% to $1.2 million in 2025, then changed by 0.0% to $1.2 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Leases are $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $565030.0 (Q3 2025).